clinical trial · NCT06289504
A Study on How CagriSema Affects Levels of Atorvastatin and Warfarin in the Blood of Participants With Excess Body Weight
Novo Nordisk A/S·phase1·completed·n = 34
ObesityCagrilintideSemaglutideAtorvastatinWarfarin
brief summary
This study will look at how CagriSema affects the blood levels of atorvastatin and warfarin. The study will look at the levels of warfarin and atorvastatin in the blood before the participant starts taking CagriSema and if this changes after the participant has taken CagriSema. The study will also investigate the effect of warfarin before and after the participant takes CagriSema and assess if the injection site affects the level of CagriSema in the blood. The study will last for about 8 months.
started
Feb 27, 2024
primary completion
Oct 16, 2024
completion
Nov 15, 2024
last updated
May 19, 2026
official title
An Open-label, One-sequence Cross-over, Single-centre Trial, Investigating the Influence of CagriSema on Pharmacokinetics and Pharmacodynamics of Warfarin and Pharmacokinetics of Atorvastatin in Participants With Overweight or Obesity
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol